MASSIVE ASCITES AND INCONCLUSIVE PERITONEAL CARCINOMATOSIS-LIKE TUMORS AS THE PRESENTING SIGN FOR INTRADUCTAL PROSTATE CARCINOMA. A CASE REPORT.

  • Dana Cernov "Prof. dr. Alexandru Trestioreanu" Institute of Oncology Bucharest, Romania
  • Irina Bondoc "Prof. dr. Alexandru Trestioreanu" Institute of Oncology Bucharest, Romania
  • Marius Zamfir "Prof. dr. Alexandru Trestioreanu" Institute of Oncology Bucharest, Romania
  • Andrei Văcărașu "Prof. dr. Alexandru Trestioreanu" Institute of Oncology Bucharest, Romania
  • Mara Mardare "Prof. dr. Alexandru Trestioreanu" Institute of Oncology Bucharest, Romania & "Carol Davila" University of Medicine and Pharmacy Bucharest, Romania
  • Irina Niță MONZA Oncology Hospital Bucharest, Romania
  • Ioana Luca MONZA Oncology Hospital Bucharest, Romania
  • Gheorghe Niță MONZA Oncology Hospital Bucharest, Romania
  • Octav Ginghină "Prof. dr. Alexandru Trestioreanu" Institute of Oncology Bucharest, Romania & "Carol Davila" University of Medicine and Pharmacy Bucharest, Romania
Keywords: prostate cancer, peritoneal carcinomatosis, ascites, metastasis

Abstract

Prostate cancer is a leading health issue for the male population, accounting for 27% of estimated cancer diagnoses in men in 2022 in the USA. The presence of metastatic prostate cancer reduces the five-year survival rate from 99% (in localized prostatic tumors) to just 30%. Peritoneal carcinomatosis from prostate cancer is highly uncommon, with only 18 cases reported. We present a rare case of metastatic prostate cancer to the parietal peritoneum, omentum and terminal ileum, associated with bone metastases. A peritoneal biopsy was performed and ascitic liquid was drawn and sent to cytologic and microbiological analysis, with no definite answer. Although a second and third anatomopathological examinations were performed by different specialists, the result remained inconclusive, suggesting a fibroblastic proliferation of unknown etiology. Further investigations were recommended, following the inconclusive biopsies and uncertainty of the origin of the peritoneal lesions, and an upper GI endoscopy and colonoscopy were performed. After a multidisciplinary tumor board evaluation of the case with consideration of the discrepancies in the histopathological findings and the patient’s status degradation, oncological treatment was initiated, targeting the prostatic cancer and metastatic bone lesions. The patient’s evolution under treatment was favorable, with a progressive reduction of the ascitic fluid, amelioration of the patient’s general status and weight gain. What made our case particular was the difficulty in diagnosing the nature of the peritoneal lesions and the etiology of the recurrent ascites, due to multiple inconclusive histopathological reports, as the peritoneal and intestinal lesions presented an uncommon histopathological aspect for a malignant lesion.

References

[1] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer Statistics, 2021,” CA: A Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, Jan. 2021, doi: 10.3322/caac.21654.
[2] M. C. King, A. Sardi, C. Velez-Mejia, M. Sittig, and P. Ledakis, “Novel Case of Isolated Peritoneal Carcinomatosis from Metastatic Prostate Cancer Carrying a Pathogenic BRCA Mutation Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy,” Urology, vol. 155, pp. 210–213, Sep. 2021, doi: 10.1016/j.urology.2021.05.026.
[3] M. Archer, N. Dogra, and N. Kyprianou, “Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance,” Cancers, vol. 12, no. 10, p. 2984, Oct. 2020, doi: 10.3390/cancers12102984.
[4] G. Gandaglia et al., “Distribution of metastatic sites in patients with prostate cancer: A population-based analysis,” The Prostate, vol. 74, no. 2, pp. 210–216, Oct. 2013, doi: 10.1002/pros.22742.
[5] S. A. Tareen, J. Rodriguez, and P. Wu, “Prostate Cancer Metastatic to the Peritoneum: A Road Less Traveled by a Common Malignancy,” Cureus, Mar. 2019, doi: 10.7759/cureus.4222.
[6] D. Petrakis et al., “An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: Case report and literature review,” Journal of Advanced Research, vol. 6, no. 3, pp. 517–521, May 2015, doi: 10.1016/j.jare.2014.05.002.
[7] V. Visconti, A. Fernandes, and I. Oliveira, “An improbable case of Ascites,” European journal of case reports in internal medicine, Dec. 2020, doi: 10.12890/2020_001474.
[8] C. van Roekel, T. G. N. Jonges, and T. M. T. W. Lock, “What are the odds? Prostate metastases to ureter and peritoneum,” BMJ Case Reports, p. bcr-2018-225730, Aug. 2018, doi: 10.1136/bcr-2018-225730
[9] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2022,” CA: A Cancer Journal for Clinicians, vol. 72, no. 1, pp. 7–33, Jan. 2022, doi: 10.3322/caac.21708.
[10] X. Ji, L. Wang, J. Lin, and K. Tang, “Detection of Diffuse Peritoneal and Omental Metastases From Prostate Cancer With 18F-PSMA-1007 PET/CT,” Clinical Nuclear Medicine, vol. 47, no. 1, pp. e74–e76, Jan. 2022, doi: 10.1097/RLU.0000000000003802.
[11] R. Rizk, E. Danse, S. Aydin, B. Tombal, and J.-P. Machiels, “Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxel-based chemotherapy,” Urologia Internationalis, vol. 93, no. 1, pp. 49–54, 2014, doi: 10.1159/000354396.
Published
2022-12-25
How to Cite
[1]
D. Cernov, “MASSIVE ASCITES AND INCONCLUSIVE PERITONEAL CARCINOMATOSIS-LIKE TUMORS AS THE PRESENTING SIGN FOR INTRADUCTAL PROSTATE CARCINOMA. A CASE REPORT.”, JSS, vol. 9, no. 4, Dec. 2022.